keyword
MENU ▼
Read by QxMD icon Read
search

Glimepiride

keyword
https://www.readbyqxmd.com/read/29786959/assessment-of-the-drug-interaction-potential-of-ertugliflozin-with-sitagliptin-metformin-glimepiride-or-simvastatin-in-healthy-subjects
#1
Vikas Kumar Dawra, David L Cutler, Susan Zhou, Rajesh Krishna, Haihong Shi, Yali Liang, Christine Alvey, Anne Hickman, Didier Saur, Steven G Terra, Vaishali Sahasrabudhe
Ertugliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of adults with type 2 diabetes mellitus, is expected to be coadministered with sitagliptin, metformin, glimepiride, and/or simvastatin. Four separate open-label, randomized, single-dose, crossover studies were conducted in healthy adults to assess the potential pharmacokinetic interactions between ertugliflozin 15 mg and sitagliptin 100 mg (n = 12), metformin 1000 mg (n = 18), glimepiride 1 mg (n = 18), or simvastatin 40 mg (n = 18)...
May 22, 2018: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29780260/efficacy-and-safety-profile-of-once-weekly-dulaglutide-in-type-2-diabetes-a-report-on-the-emerging-new-data
#2
REVIEW
Anne J Kugler, Michael L Thiman
Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering ranged from -0.78% to -1.64% over 52-104 weeks, and it consistently outperformed each of these agents. As an add-on therapy, dulaglutide provided additional A1c lowering of -1.4% to -1.44% over monotherapy with glimepiride or glargine at 24 and 28 weeks, respectively...
2018: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/29766812/switching-dipeptidyl-peptidase-4-inhibitors-to-tofogliflozin-a-selective-inhibitor-of-sodium-glucose-cotransporter-2-improves-arterial-stiffness-evaluated-by-cardio-ankle-vascular-index-in-patients-with-type-2-diabetes
#3
Nobuhiro Tahara, Sho-Ichi Yamagish, Munehisa Bekki, Atsuko Tahara, Sachiyo Igata, Akihiro Honda, Yoichi Sugiyama, Tomohisa Nakamura, Jiahui Sun, Yuki Kumashiro, Takanori Matsui, Yoshihiro Fukumoto
BACKGROUND: We have found that anagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4) significantly ameliorates arterial stiffness in type 2 diabetes mellitus (T2DM) patients compared with an equivalent hypoglycemic agent, glimepiride. However, it remains unclear whether and how switching DPP-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) improves arterial stiffness in T2DM patients. METHODS: Nineteen T2DM patients who had received DPP-4 inhibitors for at least 1 year were enrolled in this study...
May 15, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29740874/short-term-combined-treatment-with-exenatide-and-metformin-is-superior-to-glimepiride-combined-metformin-in-improvement-of-serum-testosterone-levels-in-type-2-diabetic-patients-with-obesity
#4
N Shao, X-Y Yu, Y-M Yu, B-W Li, J Pan, W-H Wu, H-J Zhang, X-F Ma, M Hao, H-Y Kuang
Men with type 2 diabetes (T2D) and obesity are often characterised by low testosterone (T). We aimed to determine whether exenatide (EXE) combined metformin (MET) treatment has a better effect on serum total testosterone (TT) levels than glimepiride (GLI) combined MET treatment in men with T2D and obesity. In a multicentre, 12-week observational study, 176 obese T2D men with failed glycaemic control were included in the study: ninety men (mean age, 43.00 ± 8.50 years) in EXE + MET group and 86 men (mean age, 44...
May 8, 2018: Andrologia
https://www.readbyqxmd.com/read/29737290/pharmacoeconomic-evaluation-of-glimepiride-combined-with-other-drugs-in-the-treatment-of-diabetes
#5
Xiufang Liu, Liping Zeng, Wenchao Xu
The goal of diabetic drug treatment is to stabilize the blood sugar for a long time to close to the normal level, to correct the metabolic disorder and eliminate the symptoms. At present, glimepiride has become commonly used drugs for the treatment of diabetes with obesity. Compared with metformin, acarbose and rosiglitazone, glimepiride has different mechanisms of drug action, clinical combination showed synergistic hypoglycemic effect, good clinical curative effect. So, we use three treatments to study as group A (glimepiride and metformin); group B (glimepiride and acarbose); Group C (glimepiride and rosiglitazone)...
May 2018: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29735458/pharmacoeconomic-evaluation-of-glimepiride-combined-with-other-drugs-in-the-treatment-of-diabetes
#6
Xiufang Liu, Liping Zeng, Wenchao Xu
The goal of diabetic drug treatment is to stabilize the blood sugar for a long time to close to the normal level, to correct the metabolic disorder and eliminate the symptoms. At present, glimepiride has become commonly used drugs for the treatment of diabetes with obesity. Compared with metformin, acarbose and rosiglitazone, glimepiride has different mechanisms of drug action, clinical combination showed synergistic hypoglycemic effect, good clinical curative effect. So, we use three treatments to study as group A (glimepiride and metformin); group B (glimepiride and acarbose); Group C (glimepiride and rosiglitazone)...
May 2018: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29729957/comparison-of-adherence-to-glimepiride-metformin-sustained-release-once-daily-versus-glimepiride-metformin-immediate-release-bid-fixed-combination-therapy-using-the-medication-event-monitoring-system-in-patients-with-type-2-diabetes
#7
Jong-Dai Kim, Cheol-Young Park, Bong-Yun Cha, Kyu Jeung Ahn, In Joo Kim, Kyong Soo Park, Hyung Woo Lee, Kyung-Wan Min, Jong Chul Won, Min Young Chung, Jae-Taek Kim, Jun Goo Kang, Sung-Woo Park
PURPOSE: The purpose of this study was to compare the adherence of the glimepiride/metformin sustained release (GM-SR) once-daily fixed-dose combination and glimepiride/metformin immediate release (GM-IR) BID fixed-dose combination in type 2 diabetes therapies. METHODS: An open-label, randomized, multicenter, parallel-group study was conducted at 11 hospitals in the Republic of Korea. A total of 168 patients with type 2 diabetes treated with >4 mg of glimepiride and 1000 mg of metformin by using free or fixed-dose combination therapy for at least 2 weeks were enrolled...
May 2, 2018: Clinical Therapeutics
https://www.readbyqxmd.com/read/29708650/efficacy-and-safety-of-dulaglutide-monotherapy-compared-to-glimepiride-in-east-asian-patients-with-type-2-diabetes-in-a-multicenter-double-blind-randomized-parallel-arm-active-comparator-phase-3-trial
#8
Yu Hong Chen, Chien-Ning Huang, Young Min Cho, Pengfei Li, Liqun Gu, Feng Wang, Jun Yang, Wei Qing Wang
AIMS: To compare the efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide 1.5 mg and 0.75 mg with glimepiride in East Asian (EA) patients with type 2 diabetes (T2D). MATERIALS AND METHODS: In this phase 3, multinational, multicenter, double-blind, randomized, parallel-arm 26-week study, patients with inadequate glycemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 mg or 0.75 mg or daily glimepiride (1-3 mg/day)...
April 30, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29678613/a-3d-printed-bilayer-oral-solid-dosage-form-combining-metformin-for-prolonged-and-glimepiride-for-immediate-drug-delivery
#9
Christos I Gioumouxouzis, Apostolos Baklavaridis, Orestis L Katsamenis, Catherine K Markopoulou, Nikolaos Bouropoulos, Dimitrios Tzetzis, Dimitrios G Fatouros
Fused Deposition Modelling (a.k.a. FDM-3D printing) has been previously employed in the development of personalized medicines with unique properties and release behavior. In the present work, a bilayer dosage form containing two anti-diabetic drugs with different daily dosage regimens; i.e. metformin and glimepiride, was manufactured via FDM 3D printing, studied using a variety of techniques and characterized in vitro. Metformin and glimepiride were embedded in Eudragit® RL sustained release layer and polyvinyl alcohol (PVA) layer respectively...
April 17, 2018: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29671019/lixisenatide-a-novel-glp-1-analog-protects-against-cerebral-ischemia-reperfusion-injury-in-diabetic-rats
#10
Rania G Abdel-Latif, Gehan H Heeba, Ashraf Taye, Mohamed M A Khalifa
Type 2 diabetes mellitus (T2DM) is a major risk factor for ischemic stroke accompanied by vascular dysfunction and poor cerebrovascular outcome. Lixisenatide is a glucagon like peptide-1 (GLP-1) analog that is recently used for T2DM treatment with established neuroprotective properties. This study investigated and compared the neuroprotective effect of lixisenatide against glimepiride on diabetic rats subjected to global cerebral ischemia/reperfusion (I/R) injury. T2DM-induced adult male Wistar rats were administered lixisenatide or glimepiride prior to induction of global cerebral I/R-induced injury...
April 18, 2018: Naunyn-Schmiedeberg's Archives of Pharmacology
https://www.readbyqxmd.com/read/29555503/characteristics-of-repaglinide-effects-on-insulin-secretion
#11
Harumi Takahashi, Shihomi Hidaka, Chihiro Seki, Norihide Yokoi, Susumu Seino
The dynamics of insulin secretion stimulated by repaglinide, a glinide, and the combinatorial effects of repaglinide and incretin were investigated. At 4.4 mM glucose, repaglinide induced insulin secretion with a gradually increasing first phase, showing different dynamics from that induced by glimepiride, a sulfonylurea. In the presence of glucagon-like peptide-1 (GLP-1), insulin secretion by repaglinide was augmented significantly but to lesser extent and showed different dynamics from that by glimepiride...
June 5, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29548934/effects-on-repetitive-24-hour-ambulatory-blood-pressure-in-subjects-with-type-ii-diabetes-randomized-to-liraglutide-or-glimepiride-treatment-both-in-combination-with-metformin-a-randomized-open-parallel-group-study
#12
Johan Jendle, Xin Fang, Yang Cao, Leif Bojö, Bo K Nilsson, Fredric Hedberg, Irene Santos-Pardo, Thomas Nyström
In this post hoc study, we aimed to investigate liraglutide treatment on repetitive 24-hour blood pressure (BP) in patients with type II diabetes. Sixty-two individuals with type II diabetes (45 males) were randomized to 1.8 mg liraglutide once daily or 4 mg glimepiride together with 1 g metformin twice daily. Ambulatory 24-hour systolic and diastolic blood pressure (sBP/dBP) was repetitively measured at baseline, 2 weeks, and 18 weeks. Outcomes were evaluated as treatment change from baseline, 2 weeks, and 18 weeks...
May 2018: Journal of the American Society of Hypertension: JASH
https://www.readbyqxmd.com/read/29537664/the-pattern-of-prescribing-of-glucose-modulating-agents-for-type-2-diabetes-in-general-practices-in-england-2016-17
#13
Adrian H Heald, Mark Livingston, Zuzanna Bien, Gabriela Y C Moreno, Ian Laing, Mike Stedman
BACKGROUND: In the financial year 2016/17 there were 52.0 million items prescribed for diabetes at a total net ingredient cost of £983.7 million - up from 28.9 million prescription items and £572.4 million in 2006/07. Anti-diabetes drugs (British National Formulary section 6.1.2) make up 45.1 per cent of the total £983.7 million net ingredient cost of drugs used in diabetes and account for 72.0 per cent of prescription items for all diabetes prescribing. METHODS: We examined the way that agents licensed to treat type 2 diabetes were used across GP practices in England in the year 2016/2017...
March 14, 2018: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/29535952/consensus-recommendations-on-sulfonylurea-and-sulfonylurea-combinations-in-the-management-of-type-2-diabetes-mellitus-international-task-force
#14
REVIEW
Sanjay Kalra, Silver Bahendeka, Rakesh Sahay, Sujoy Ghosh, Fariduddin Md, Abbas Orabi, Kaushik Ramaiya, Sameer Al Shammari, Dina Shrestha, Khalid Shaikh, Sachitha Abhayaratna, Pradeep K Shrestha, Aravinthan Mahalingam, Mazen Askheta, Aly Ahmed A Rahim, Fatimah Eliana, Hari K Shrestha, Sandeep Chaudhary, Nancy Ngugi, Jean Claude Mbanya, Than Than Aye, Tint Swe Latt, Zhanay A Akanov, Abbas Raza Syed, Nikhil Tandon, A G Unnikrishnan, S V Madhu, Ali Jawa, Subhankar Chowdhury, Sarita Bajaj, Ashok Kumar Das
For decades, sulfonylureas (SUs) have been important drugs in the antidiabetic therapeutic armamentarium. They have been used as monotherapy as well as combination therapy. Focus on newer drugs and concerns about the risk of severe hypoglycemia and weight gain with some SUs have led to discussion on their safety and utility. It has to be borne in mind that the adverse events associated with SUs should not be ascribed to the whole class, as many modern SUs, such as glimepiride and gliclazide modified release, are associated with better safety profiles...
January 2018: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29503528/formulation-design-and-development-of-matrix-diffusion-controlled-transdermal-drug-delivery-of-glimepiride
#15
Muhammad Rouf Akram, Mahmood Ahmad, Asad Abrar, Rai Muhammad Sarfraz, Asif Mahmood
Background: The present work was conducted to prepare and evaluate transdermal patches with optimization of suitable polymeric blend of poly(meth) acrylates (Eudragit® ) (Ammonio Methacrylate Copolymer Ph Eur) for sustained transdermal delivery of glimepiride. Method: Polymeric matrix transdermal films were prepared by using Ammonio Methacrylate Copolymer Ph Eur RL 100 and Ammonio Methacrylate Copolymer Ph Eur RS 100 as the film former, and dibutyl phthalate (30% w/w) as the plasticizer...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29501322/do-sulphonylureas-still-have-a-place-in-clinical-practice
#16
REVIEW
Kamlesh Khunti, Sudesna Chatterjee, Hertzel C Gerstein, Sophia Zoungas, Melanie J Davies
Sulphonylureas have been commercially available since the 1950s, but their use continues to be associated with controversy. Although adverse cardiovascular outcomes in some observational studies have raised concerns about sulphonylureas, findings from relatively recent, robust, and high-quality systematic reviews have indicated no increased risk of all-cause mortality associated with sulphonylureas compared with other active treatments. Results from large, multicentre, randomised controlled trials such as the UK Prospective Diabetes Study and ADVANCE have confirmed the microvascular benefits of sulphonylureas, a reduction in the incidence or worsening of nephropathy and retinopathy, and no increase in all-cause mortality, although whether these benefits were due to sulphonylurea therapy and not an overall glucose-lowering effect could not be confirmed...
February 28, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29498478/interaction-of-sulfonylureas-with-liver-uptake-transporters-oatp1b1-and-oatp1b3
#17
Yu Chen, Lin Chen, Hong Zhang, Shibo Huang, Yuqing Xiong, Chunhua Xia
Sulfonylureas (SUs) such as glibenclamide, gliclazide, glimepiride, glipizide and gliquidone are one of the first oral medicines available for the treatment of type 2 diabetes and are widely used for the treatment of hyperglycaemia. The hepatic transporters, organic anion transporting polypeptide 1B1 (OATP1B1) and organic anion transporting polypeptide 1B3 (OATP1B3), play an important role in the disposition of a variety of drugs by mediating their uptake from blood into hepatocytes. Drug-drug interactions mediated by OATP1B1/1B3 may result in the hepatic transporting change for drug substrates...
March 2, 2018: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29493662/corrigendum-effects-on-subclinical-heart-failure-in-type-2-diabetic-subjects-on-liraglutide-treatment-vs-glimepiride-both-in-combination-with-metformin-a-randomized-open-parallel-group-study
#18
Thomas Nyström, Irene Santos-Pardo, Fredric Hedberg, Johan Wardell, Nils Witt, Yang Cao, Leif Bojö, Bo Nilsson, Johan Jendle
[This corrects the article on p. 325 in vol. 8, PMID: 29184539.].
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29493100/glucose-excursions-and-hypoglycemia-in-patients-with-type-2-diabetes-treated-with-mitiglinide-voglibose-versus-glimepiride-a-randomized-cross-over-trial
#19
Kanta Fujimoto, Yui Shibayama, Eriko Yamaguchi, Sachiko Honjo, Akihiro Hamasaki, Yoshiyuki Hamamoto
BACKGROUND: Glucose excursions and hypoglycemia are associated with cardiovascular complications. However, no studies have evaluated glucose excursions and the frequency of hypoglycemia in patients treated with mitiglinide/voglibose versus glimepiride as add-on to dipeptidyl peptidase-4 inhibitor therapy. METHODS: This cross-over trial included 20 patients with type 2 diabetes. After initiating vildagliptin 100 mg, patients were randomly assigned to receive mitiglinide 10 mg/voglibose 0...
March 1, 2018: Journal of Diabetes
https://www.readbyqxmd.com/read/29492878/liver-safety-of-fasiglifam-tak-875-in-patients-with-type-2-diabetes-review-of-the-global-clinical-trial-experience
#20
John F Marcinak, Melvin S Munsaka, Paul B Watkins, Takashi Ohira, Neila Smith
INTRODUCTION: Fasiglifam (TAK-875) is a G protein-coupled receptor 40 agonist that was being investigated for treatment of type 2 diabetes mellitus (T2DM). A development program was terminated late in phase III clinical trials due to liver safety concerns. METHODS: The liver safety of fasiglifam was assessed from data based on six phase II and nine phase III double-blind studies and two open-label studies with emphasis on pooled data from 15 double-blind studies from both global and Japanese development programs...
February 28, 2018: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
keyword
keyword
32897
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"